Introduction
Ischemic stroke is a destructive cerebrovascular disease and a leading cause of death worldwide. 1 Currently, recombinant tissue plasminogen activator is the only therapeutic agent available for the treatment of ischemic stroke. However, ,5% of patients with stroke recover, owing to the narrow therapeutic window, 2,3 risk of intracerebral hemorrhage, and multiple contraindications. 4 Given the devastating impact and social burden of this damaging cerebrovascular event, the development of optimum treatments for ischemic stroke is urgently needed. 5 Abundant evidence has confirmed that the disruption of the blood-brain barrier (BBB) and the consequent brain edema are major contributors to the pathogenesis of ischemic stroke. Intravascular proteins and fluid penetrate into the cerebral parenchymal extracellular space, leading to vasogenic cerebral edema and reduced blood flow to neurons, resulting in an irreversible apoptosis. 6, 7 The BBB is not a rigid structure but a dynamic interface, with a range of interrelated functions that result from effective tight junctions (TJs), trans-endothelial transport systems, enzymes, and the regulation of leukocyte permeation. TJs are the most apical structure within the intercellular cleft, submit your manuscript | www.dovepress.com
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cao et al limiting the paracellular flux of hydrophilic molecules across the BBB. TJs consist of several types of integral transmembrane and cytoplasmic accessory proteins, of which occludin and zona occludens-1 (ZO-1) play key roles in BBB dysfunction after ischemic stroke. 8, 9 Thus, protecting the BBB may be a promising strategy for developing new clinical therapies for ischemic stroke. 10 A number of studies have indicated that traditional Chinese medicine preparations, such as XueShuanTong injection (XST), 11 Danhong injection, 12 and Buyanghuanwu decoction, 13 have reliable curative efficacy in the prevention and treatment of stroke. YiQiFuMai powder injection (YQFM), a modern preparation based on a well-known complex prescription, Sheng-Mai-San, was approved in 2007 by the China Food and Drug Administration for the treatment of microcirculatory disturbance-related diseases in the People's Republic of China. 14, 15 YQFM is composed of Panax ginseng CA Mey., Ophiopogon japonicus (Thunb.) Ker-Gawl, and Schisandra chinensis (Turcz.) Baill (1:3:1.5). 16 The bioactive compounds and their chemical structures were identified by tandem mass spectrophotometry in negative electrospray ionization mode. 17 Considerable numbers of previous studies have indicated that YQFM is widely used for the treatment of cardiovascular disease. 17, 18 We previously predicted the multitarget mechanism of YQFM in cardiocerebral ischemic disease, based on network pharmacology. 19 However, its related pharmacological activity and potential mechanism in ischemic stroke in animals remain unclear. Therefore, in the current study, we investigated the effects of YQFM on brain edema and BBB dysfunction induced by cerebral ischemia-reperfusion (I/R) compared with XST and explored the possible modulation of TJs in I/R induced by middle cerebral artery occlusion (MCAO) in mice. Our findings provide some evidence for the clinical application of YQFM in ischemic stroke.
Materials and methods reagents
YQFM (batch number 20121210) was purchased from Tasly Pharmaceutical Co., Ltd. (Tianjin, People's Republic of China). An ultrahigh performance liquid chromatography (UHPLC) fingerprint ( Figure 1 ) was used to control the quality of YQFM in the current study. Based on this fingerprint, we established an optimum and easily controlled method for the analysis of YQFM in our laboratory. 18 XST was purchased from Livzon Pharmaceutical Group Inc. (Guangdong, People's Republic of China). Fluorescein-isothiocyanate-conjugated goat antirabbit immunoglobulin G and horseradish-peroxidase-conjugated goat antirabbit and anti-mouse immunoglobulin G were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). All chemicals were of the commercially available highest purity.
UhPlc analysis
The injection of YQFM was prepared as reported previously. 13 A UHPLC system (Acquity™ UPLC; Waters Corporation, Milford, MA, USA), equipped with a diode-array detection (DAD) system and a Zorbax Eclipse plus C 18 column (50 mm ×2.1 mm ×1.8 µm), was used for the UHPLC analysis. The monitoring detection was set at 203 nm, and diodearray detection spectra were recorded from 190 to 400 nm. The sample injection volume was 5 µL, and the mobile phase was water:formic acid (100:0.01, v/v) (A) and acetonitrile (B). The UPLC eluting conditions were as follows: 2%-20% B for 0-3 minutes; 20%-30% B for 3-9 minutes; 30%-38% B for 9-12 minutes; 38%-40.5% B for 12-14.5 minutes; 
Focal cerebral i/r
Stroke was induced by MCAO and reperfusion in C57BL/6J mice as reported previously. 20 Briefly, each mouse was anesthetized with 4% chloral hydrate (0.1 mL per 10 g body weight) IP, then the neck vessels were exposed by a midline incision, and the branches of the right external carotid artery were carefully isolated and cauterized. A 6-0 nylon monofilament suture, blunted at the tip and coated with 1% poly-l-lysine, was advanced 9-10 mm into the internal carotid to occlude the origin of the middle cerebral artery. The temperature of the animal was maintained at 37.0°C±0.5°C with a heating pad (ALCBIO, Shanghai, People's Republic of China) during surgery and ischemia. The same treatment was carried out on mice in that sham group except that the suture was not advanced into the internal carotid artery. A laser Doppler flowmeter (FLPI2, Moor Instruments Ltd., Axminster, UK) was used to confirm that middle cerebral artery blood flow had decreased ,30% of the basic cerebral blood flow (CBF) immediately after the occlusion to. 21 Animals whose blood flow decreased ,30% of pre-ischemia levels were used for further study.
evaluation of infarct volume, neurological deficits, and brain water content
To confirm whether YQFM exerts protective effects in mice, the animals were randomly divided into six groups (n=6 for each group): sham, I/R, YQFM (dissolved in 0.9% sodium chloride at three doses of 0.336, 0.671, and 1.342 g/kg), and XST (also dissolved in 0.9% sodium chloride at a dose of 40 mg/kg in accordance with clinical practice). After MCAO for 1 hour, mice were given YQFM or an equal volume of 0.9% sodium chloride by IP administration. After 24 hours of reperfusion, mice were anesthetized with 4% choral hydrate IP; after the animals were dead, the brains were removed, dissected, and sliced; and then five slices (1.5 mm thickness) were sectioned and incubated with 1% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich Co., St Louis, MO, USA) for 30 minutes in the dark and then fixed with 4% paraformaldehyde (PFA). Lesioned areas that did not stain red with TTC were quantitatively analyzed by Quantity One analysis software (Bio-Rad Laboratories Inc., Hercules, CA, USA). Infarct volume was calculated using slice thickness and the measured areas of the lesion. Data are expressed as a percentage of total hemispheres. 22 Behavioral assessment was performed 24 hours after reperfusion. Neurological deficits of the experimental animals were graded on an 18-point scale as previously described. 23 The measurement of neurological deficits consisted of the following tests: spontaneous activity, symmetry of movements, symmetry of forelimbs, climbing, reaction to touch, and response to vibrissae touch. All six individual tests were scored on a four-point scale as 3, 2, 1, or 0. Final score was obtained by adding the scores recorded for each individual test, with a maximum score of 18 observed in healthy animals. Brain water content (n=6 for each group) was determined 24 hours after reperfusion, using the wet-dry method as described previously. 24 The total brain water was calculated as:
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cBF measurement CBF was measured using laser Doppler flowmetry as described in the "Materials and methods" section. 20 A computer-controlled optical scanner directed a low-power laser beam over the exposed cortex. The scanner head was positioned parallel to the cerebral cortex at a distance of ~20 cm. 25 A color-coded image indicating specific relative perfusion levels was displayed on a video monitor. The images were acquired at the onset of ischemia and reperfusion for 24 hours (n=6 for each group).
hematoxylin and eosin staining of adjacent brain sections (5 µm thick) were cut from the coronal plane of the wax-embedded tissue and were stained with H&E for histomorphological analysis conducted by a pathologist blinded to the treatment groups. 26 18 F-fluorodeoxyglucose-positron emission tomography imaging 18 F-fluorodeoxyglucose-micro-positron emission tomography ( 18 F-FDG-micro-PET) scans were performed in mice (n=3 for each group) anesthetized at 23 hours after reperfusion with 4% isoflurane, with anesthesia maintained with 2%-2.5% of isoflurane in 100% O 2 . The tail vein was catheterized with a gauge catheter for intravenous administration of the radiotracer (radiochemical purity was .95%; provided by Mitro Biotech Co. Ltd., Nanjing, People's Republic of China). Animals were placed into a mouse holder compatible with PET acquisition systems (Trans-PET ® Bio-Caliburn ® 700; X-Z LAB, Inc., San Ramon, CA, USA), and normothermia was maintained by a water-based heating blanket. 27 Animals underwent two micro-PET scans to assess glucose metabolism of 18 F-FDG for each time point and condition (before ischemia and 24 hours after I/R).
evaluation of BBB permeability BBB permeability was assessed by the leakage of Evans Blue (EB) stain into the brain following the tail-vein injection. 28 Two hours before the animals (n=6 for each group) were euthanized, 0.1 mL per 10 g body weight of 2% EB (SigmaAldrich) in normal saline was injected into each animal. The animals were then anesthetized and perfused with normal saline. For the quantitative measurement of EB leakage, the ipsilateral hemisphere was removed and homogenized in 1 mL of trichloroacetic acid, then centrifuged at 12,000× g for 20 minutes. EB concentration was quantitatively determined by measuring the absorbance at 620 nm of the supernatant with a spectrophotometer. The EB content was quantified as micrograms of EB per gram of tissue, using a standard curve. 29 
Western blotting
Western blotting (n=3 for each group) was performed as described previously. 25, 28 Proteins extracted from the cortex of the ischemic side in the operated mice, and the corresponding areas of sham-operated mice were used for Western blot analysis. Membranes were incubated overnight at 4°C with the appropriate primary antibodies: ZO-1 (1:100; ab59720), occludin (1:200; ab31721) (both were purchased from Abcam, Cambridge, UK), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:8000; Kangchen Bio-tech Inc., Shanghai, People's Republic of China). After washing, the membrane was incubated with horseradish-peroxidase-conjugated secondary antibody for 1.5 hours. Immunoreactive bands were detected by a chemiluminescence system (ECL Plus; Amersham, Arlington Heights, IL, USA) and analyzed by Quantity One analysis software. GAPDH was used as the loading control, as in previous reports. 30, 31 Each sample was normalized first against the GAPDH level in the sample, then against the level of the sham sample, as described previously. 30, 31 Immunofluorescence staining Mice (n=3 for each group) were anesthetized IP with 4% chloral hydrate (0.1 mL/10 g body weight) and transcardially perfused with 100 mL of normal saline, followed by 100 mL of 0.1 M phosphate-buffered saline (PBS) containing 4% PFA (pH =7.4).
28 Perfusion-fixed brains were postfixed in 0.1 M PBS +4% PFA overnight, followed by dehydration in 40% sucrose. Coronal brain sections (20 µm thick) were cut on a cryostat (CM1950; Leica Microsystems, Wetzlar, Germany), and the sections were blocked for 1.5 hours in 5% bovine serum albumin in PBS with 0.1% Triton X-100. The sections were then incubated overnight at 4°C in 3% bovine serum albumin in 0.1% Triton X-100/PBS with the primary antibodies: anti-ZO-1 TJ protein antibody (1:50; ab59720) and anti-occludin antibody (1:100; ab31721) (both were purchased from Abcam). After being rinsed three times with PBS, sections were incubated for 2 hours in fluorochromecoupled secondary antibody. The nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; Boyetime Institute of Biotechnology, Shanghai, People's Republic of China). After being rinsed with PBS, the sections were examined under a fluorescence microscope (Leica Microsystems).
statistical analysis
All results are expressed as mean ± standard deviation. Statistical analysis was carried out using Student's two-tailed t-test for comparison between two groups and one-way analysis of variance followed by Dunnett's test when the data involved three or more groups. P,0.05 was considered statistically significant. 32 All analyses were performed with GraphPad Prism software (Version 5.01; GraphPad Software, Inc., La Jolla, CA, USA). 
Results
YQFM reduces infarction volume and brain water content and improves behavioral outcomes in i/r-treated mice
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YQFM ameliorates cerebral i/r-induced brain injury
Representative samples of TTC-stained brain sections are shown in Figure 2A , with corresponding infarction volumes and statistical data that are shown in Figure 2B . Infarct volume was significantly increased in the shamoperated reference group (37.4%±8.6%), whereas the three doses of YQFM (0.336, 0.671, and 1.342 g/kg) reduced the infarct volumes induced by I/R by 28.7%±3.6%, 25.2%±2.7%, and 13.9%±1.4%, respectively, with the highest inhibition rate being 62.83% (YQFM at a dose of 1.342 g/kg versus model group). XST at a dose of 40 mg/ kg, the positive control, also significantly reduced I/Rinduced infarct volume.
As shown in Figure 2C , there was a marked decline of 10.67±0.51 in I/R neurological score, while the YQFM and XST treatments resulted in a statistically significant improvement in neurobehavioral deficits compared with the reference group (P,0.05). Furthermore, the reference group had significantly increased brain water content (80.5%±0.6% versus 78.6%±0.7%, P,0.05), which was significantly attenuated by YQFM at all three doses and by XST ( Figure 2D ).
YQFM increases cBF in i/r-treated mice
CBF was determined by a laser Doppler perfusion imaging system in the different groups, as shown in Figure 3A , and the quantification of the results is shown in Figure 3B . The administration of both YQFM at a dose of 1.342 g/kg and XST at a dose of 40 mg/kg resulted in a significant increase in CBF at 24 hours after reperfusion (63.9%±5.9% versus 27.6%±6.4%, YQFM at a dose of 1.342 g/kg versus model group, P,0.05), and increased in the other two groups (0.334 and 0.671 g/ kg) to a certain extent (42.1%±4.6% and 51.4%±6.0%). The highest inhibition rate of YQFM was 56.8% (YQFM at a dose of 1.342 g/kg versus model group).
YQFM attenuates BBB disruption in i/r-treated mice
Quantitative spectrometry detected extensive EB leakage in I/R group compared with the sham group at 24 hours after reperfusion (2.61±0.54 versus 0.21±0.08 µg/g, P,0.05). YQFM treatment significantly reduced the leakage of EB at all three doses (1.48±0.76, 1.29±0.52, and 0.87±0.61 µg/g at 0.336, 0.671, and 1.342 g/kg, respectively), and XST had Figure 4A and B) . The highest inhibition rate of YQFM was 66.67%.
YQFM ameliorates brain metabolism and histopathological damage in i/r-treated mice
Brain sections of the sham group, the untreated I/R group, and the I/R group treated with YQFM at a dose of 1.342 g/kg were examined. Figure 3A and B shows the brain metabolism and histopathological changes after 1 hour of occlusion and 24 hours of reperfusion by micro-PET imaging and H&E staining, respectively. Brain sections of the I/R group showed weak signal intensity and signal volume in the lesion side ( Figure 5A ), as well as neuronal loss and the presence of numerous vacuolated spaces ( Figure 5B ). The data showed that YQFM pretreatment at a dose of 1.342 g/kg ameliorated 
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YQFM ameliorates cerebral i/r-induced brain injury brain metabolism and histopathological damage in I/Rtreated mice by increasing the signal intensity and signal volume and decreasing the cell loss.
YQFM increases expression of ZO-1 and occludin in i/r-treated mice
To identify the relationship between TJ remodeling and BBB integrity, Western blotting and immunofluorescence staining were used to analyze the expression of TJ proteins. Western blot analysis ( Figure 6A and B) showed that the expression of ZO-1 and occludin was decreased in the I/R-treated mice, whereas it increased significantly in response to YQFM treatment at a dose of 1.342 g/kg. No statistical significance was observed with the other two YQFM groups.
We performed CD31/ZO-1 and CD31/occludin double staining, which showed that ZO-1 and occludin were continuously present in the endothelial cell layer of microvessels in normal brains treated with YQFM at a dose of 1.342 g/kg ( Figure 6C and D) . After I/R, ZO-1 and occludin showed structure disruptions with rearrangements compared with sham mice. TJs were much smoother and had more continuous labeling in the group treated with YQFM at a dose of 1.342 g/kg.
Discussion
A number of studies have demonstrated that YQFM can be used in cardiovascular diseases with marked efficacy. 14, 17 However, its protective effects in ischemic stroke remain unclear. The results of the current study revealed that YQFM produces a significant improvement in cerebral infarction, neurological score, and brain edema at doses of 0.336, 0.671, and 1.342 g/kg, showing the same effects as seen with XST (Figure 2A-D) . XST, a well-known Chinese herbal preparation, is composed of Panax notoginseng saponins, which shows part similarity to the chemical components of YQFM, and has been approved by the China Food and Drug Administration for the treatment of patients with some ischemic diseases. 11, 33, 34 The findings of the current study provide the Considering that the severity of ischemic damage correlates with the degree of CBF reduction, 35 we also investigated the changes in CBF in the different groups and found that the treatment with YQFM at a dose of 1.342 g/kg significantly increased CBF ( Figure 3A and B) , which indicated that the smaller infarct volume in the YQFM-treated groups was correlated with improved CBF during I/R. However, molecular imaging has a number of advantages, such as the visual representation, characterization, and quantification of biological processes at cellular and molecular levels. 36, 37 PET with 18 F-FDG has been widely used in the evaluation of the effects of drugs for cerebrovascular disease via the quantitative and noninvasive monitoring of glucose metabolism. 12, 38, 39 In the current study, micro-PET imaging technology was used to further confirm the validity of YQFM treatment in I/R-treated mice. We found that YQFM improved brain glucose metabolism, which was consistent with the results of TTC staining ( Figure 5A ). In addition, H&E staining for histopathological observations suggested that neural structure was recovered, with a dense neuropil and largely viable 
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YQFM ameliorates cerebral i/r-induced brain injury neurons, in the brains of the YQFM-treated group compared with the I/R group ( Figure 5B ). These findings provide further evidence of the effectiveness of YQFM in I/R-treated mice at both the functional and the morphological levels.
Ischemic-stroke-induced brain injury is a complex pathophysiological process, including multifactor, multiway, and multichannel damage. [40] [41] [42] [43] However, BBB disruption is a critical event in the progression of ischemic stroke, which can increase cerebral vascular permeability and lead to the formation of brain edema. 44, 45 Therefore, approaches focusing on the subsequent damage of BBB dysfunction should be considered. 46, 47 The understanding of BBB dysfunction induced by ischemic stroke following thrombolytic therapy remains a challenge for clinicians. 48, 49 In the current study, the results showed that YQFM treatment significantly reduced the leakage of EB at three doses ( Figure 4A and B), which indicated that YQFM could effectively protect BBB integrity.
Furthermore, it has been generally believed that TJs that mediate paraendothelial transport participate in endothelial cell-mediated BBB permeability. 7, 50 TJs such as ZO-1 and occludin have different molecular structures and characteristics, and their degradation plays a key role in ischemic BBB dysfunction in stroke. [51] [52] [53] Loss and degradation of ZO-1 play significant roles in maintaining the continuity and integrity of TJs, which is closely linked to increases in BBB permeability. 54 Occludin, the first integral transmembrane protein to be identified, is localized to TJs. 55 Although much has been learned about TJs, the exact mechanisms of action of YQFM on TJs are not clear. Our immunofluorescence microscopy and Western blot assays demonstrated that ZO-1 and occludin participate in the modulation of BBB permeability by YQFM ( Figure 6A-D) . However, the role of the basal lamina and other TJ proteins in the action of YQFM on BBB permeability is unknown and needs further clarification.
As previously described, 18 YQFM consists of bioactive compounds, such as ginsenoside Rb1, ginsenoside Rg1, and schisandrin, some of which display neuroprotective effects after cerebral I/R injury. Recent studies have indicated that ginsenoside Rb1 can protect the loss of BBB integrity by suppressing neuroinflammation, while Rg1 attenuates BBB disruption through downregulating the expression of aquaporin 4 induced by ischemic stroke in animals. 56, 57 This indicates that these components identified by UHPLC might be the key active ingredients for BBB protection. Furthermore, the possible mechanisms of action of YQFM are linked with the nuclear factor (NF)-κB and Akt pathways, [58] [59] [60] [61] and 12 other major signaling pathways, including NF-κB, mitogen-activated protein kinase, the cytokine network, and mammalian target of rapamycin (mTOR), have been identified as related to the effects of YQFM in cardiocerebral ischemic diseases. 19 Moreover, ginsenoside Rg1 can ameliorate I/R-induced BBB disruption by regulating protease-activated receptor-1 (PAR-1), while ginsenoside Rb1 protects I/R-induced BBB disruption by inhibiting matrix metalloproteinase-9 (MMP-9). 56, 58 These findings indicate that the potential targets or pathways of YQFM in the treatment of ischemic stroke are related to PAR-1, MMP-9, NF-κB, etc. In addition, a combination of four active compounds derived from Sheng-Mai-San was reported to alleviate cerebral I/R injury, correlating with the inhibition of autophagy and modulation of the adenosine monophosphate-activated protein kinase/mTOR and Jun kinase pathways and to inhibit H 2 O 2 -induced PC12 cell apoptosis in vitro. 20, 62 Ginsenoside Rg1 can also improve cell viability and cell apoptosis induced by oxygen-glucose deprivation in cultured hippocampal neurons. 63 These findings suggest that YQFM may attenuate cerebral I/R injury via multiple mechanisms, such as anti-inflammation, antiapoptosis, antioxidation, and inhibition of autophagy, which require further investigation in future studies.
Conclusion
The current study demonstrates that the compound Chinese medicine YQFM can attenuate I/R-induced brain injury by improving cerebral infarction, neurological score, brain edema, brain metabolism, and histopathological damage. The repair of BBB disruption is mediated by interference with TJ protein degradation in vascular endothelial cells. These findings provide solid evidence for the efficacy of YQFM in the treatment of ischemic stroke.
